SCHEMBL18809145

SCHEMBL18809145

CC(=O)Oc1nc(Cl)c(Br)cc1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALOX5 P09917 1/20 0.35
POLB P06746 2/20 0.34
PKM P14618 1/20 0.33
KDM4E B2RXH2 3/20 0.33
GAA P10253 3/20 0.33
GLA P06280 2/20 0.33
GFER P55789 1/20 0.33
ACHE P22303 2/20 0.32
LMNA P02545 3/20 0.32
HTT P42858 2/20 0.31
MAPT P10636 2/20 0.31
HSD17B10 Q99714 2/20 0.31
TP53 P04637 1/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16027801 0.82 SNCA (0.35) ALOX5POLB
SCHEMBL27878809 0.80 ALOX5 (0.35) ALOX5POLBPKMKDM4EGAA
SCHEMBL17336323 0.74 EGLN1 (0.39) LMNA
SCHEMBL17336334 0.72 PTGDR2 (0.39) ABCB11
SCHEMBL6058682 0.72 TDP1 (0.50) ALDH1A1MAPK1SMN1; SMN2ALOX5KDM4E
SCHEMBL16028104 0.70 FFAR1 (0.34)
SCHEMBL27703245 0.70 LMNA (0.38) ALDH1A1MAPK1SMN1; SMN2ALOX5KDM4E
SCHEMBL4949836 0.70 KDM4E (0.35) ALDH1A1MAPK1SMN1; SMN2ALOX5POLB
SCHEMBL17607619 0.70 ALDH1A1 (0.46) ALDH1A1MAPK1SMN1; SMN2POLBPKM
SCHEMBL31586748 0.70 NPSR1 (0.44) ALDH1A1MAPK1SMN1; SMN2POLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738653-B2 Fused furans for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-22 US disclosed
EP-2970174-B1 FUSED FURANS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2017-05-03 EP disclosed